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Summary
Background and Objectives: Perioperative pain in children can be effectively
managed with systemic opioids, but addition of paracetamol or nonsteroidal
anti-inflammatory drugs (NSAIDs) may reduce opioid requirements and
potentially improve analgesia and/or reduce adverse effects.
Methods: A systematic literature search was conducted to identify trials eval-
uating postoperative opioid requirements in children and comparing NSAID
and/or paracetamol with placebo. Studies were stratified according to design:
continuous availability of intravenous opioid (PCA/NCA) vs intermittent ‘as
needed’ bolus; and single vs multiple dose paracetamol/NSAIDs. Primary out-
come data were extracted, and the percentage decrease in mean opioid con-
sumption was calculated for statistically significant reductions compared with
placebo. Secondary outcomes included differences in pain intensity, adverse
effects (sedation, respiratory depression, postoperative nausea and vomiting,
pruritus, urinary retention, bleeding), and patient/parent satisfaction.
Results: Thirty-one randomized controlled studies, with 48 active treatment
arms compared with placebo, were included. Significant opioid sparing was
reported in 38 of 48 active treatment arms, across 21 of the 31 studies. Benefit
was most consistently reported when multiple doses of study drug were
administered, and 24 h PCA or NCA opioid requirements were assessed. The
proportion of positive studies was less with paracetamol, but was influenced
by dose and route of administration. Despite availability of opioid for titra-
tion, a reduction in pain intensity by NSAIDs and/or paracetamol was
reported in 16 of 29 studies. Evidence for clinically significant reductions in
opioid-related adverse effects was less robust.
Conclusion: This systematic review supports addition of NSAIDs and/or
paracetamol to systemic opioid for perioperative pain management in
children.
Introduction
Systemic opioids are utilized for management of perioper-
ative pain in children of all ages (1,2). As there are
significant developmental changes in both the
pharmacokinetic and pharmacodynamic profile of
opioids, doses need to be adjusted according to age and
weight and titrated against individual response to optimize
analgesia and minimize adverse effects (3,4). This can be
achieved by a range of systemic opioid delivery methods,
including continuous background infusion, scheduled
intermittent boluses (5), nurse-controlled analgesia (NCA)
(2), or patient-controlled analgesia (PCA) (1).
Multi-modal analgesia is recommended for the man-
agement of pediatric perioperative pain (3,6,7) and has
the potential to improve analgesic efficacy by simulta-
neously targeting different analgesic mechanisms and/or
reducing the dose requirements of single agents, thereby
minimizing dose-dependent adverse effects. Addition of
nonsteroidal anti-inflammatory drugs (NSAIDs) and/or
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paracetamol (acetaminophen) to postoperative opioid
regimes is well supported by analyses of adult data (8–
11). The quantity and quality of evidence related to
pediatric perioperative pain management continue to
increase (3,12), and a recent meta-analysis reported a
decrease in opioid dose requirements by perioperative
NSAID administration in children (13).
Variations in design methodology and assessment
tools can influence the sensitivity of pediatric analgesic
clinical trials (14). This qualitative systematic review
aims to stratify evidence according to study design and
sensitivity and use within study comparisons to assess
the degree to which addition of NSAIDs and/or paracet-
amol alters postoperative systemic opioid requirements
in children. In addition, changes in secondary outcomes
(pain scores, drug-related adverse effects, and patient or
parental satisfaction) will be summarized.
Methods
Search strategy
Relevant studies were identified by searching electronic
databases (PubMed, Embase, CINAHL, Cochrane
Library, NHS Evidence) for randomized controlled
trials (RCTs) evaluating combinations of systemic
paracetamol and/or NSAIDs with systemic opioids for
postoperative pain management in children. Key words
were used to identify the ‘population’ (Children, Pediat-
ric, Pediatric, Neonate, Child, Newborn), ‘intervention’
(paracetamol OR acetaminophen OR NSAIDs OR indi-
vidual drug names AND opioid OR individual opioid
names), and ‘outcomes’ (opioid sparing, morbidity, pain
score, sedation, respiratory depression, PONV, pruritus,
urinary retention, and patient/parent satisfaction). Titles
and abstracts up to January 2012 were included in the
search. Additional relevant titles were identified by man-
ual search of original articles, reviews, and related corre-
spondence. Data were identified, extracted, and
presented in accordance with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines (www.prisma-statement.org).
Selection criteria
The full reports of RCTs were retrieved and evaluated.
Two authors (I.W. and C.St.JG.) independently assessed
whether studies met the inclusion criteria, and all three
authors discussed and resolved any discrepancies. Crite-
ria for inclusion included the following:
1. Study type: double blind, placebo-controlled trials
quantifying the effect of paracetamol and/or NSAID
vs placebo on systemic opioid requirements;
2. Participants: children (0–18 years) undergoing sur-
gery under general anesthesia;
3. Interventions: multiple or single doses of study drug
(paracetamol or NSAID) were administered periop-
eratively (defined as the first dose administered within
an hour prior to induction or following wound
closure) by any systemic route (oral, rectal, intramus-
cular, or intravenous).
Studies were excluded if they had no control group,
ongoing regional analgesia, or nonstandardized use of
other analgesics that could confound the opioid dose
requirements.
Data extraction
Details of the study protocol were extracted and tabu-
lated, including: age range of patients; number of
patients in each treatment arm; type(s) and duration of
surgery; dose regimes for study drugs and opioid (dose,
frequency, timing, route and method of delivery);
method of pain assessment; criteria for opioid adminis-
tration; adverse effects; and duration of follow-up. Each
included study was graded for quality and scored using
the Jadad criteria (15). In addition, the retrieved reports
were grouped according to the following aspects of
study design:
1. Continuous availability of intravenous opioid
titrated according to individual response by PCA,
NCA, or variable rate continuous infusion;
2. Intermittent as needed opioid bolus administration;
3. Use of regular repeated doses of paracetamol/NSA-
IDs for at least 24 h;
4. Use of single dose or less than 6 h paracetamol/NSA-
IDs.
Secondary outcome data were extracted and included
measures of (i) potential opioid-related adverse effects
(sedation, respiratory depression, postoperative, nausea
and vomiting, pruritus, and urinary retention); (ii)
NSAID (increased bleeding, renal dysfunction) and par-
acetamol (overdose/toxicity) adverse effects; (iii) pain
scores; and (iv) patient and/or parent satisfaction.
Analysis
The primary outcome was opioid dose requirement in
the postoperative period. Studies are reported as ‘posi-
tive’ if a statistically significant reduction in opioid
requirements was documented in pair-wise comparisons
between the treatment (i.e., paracetamol and/or
NSAID) and placebo arm, as previously used in an anal-
ysis of similar adult trials (16). The difference between
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the means of the treatment arms was expressed as a
percentage of the corresponding value in the placebo
group ([placebo—treatment/placebo] 9100). Treatment
groups in which opioid consumption was not statisti-
cally significantly different from the placebo group were
designated as ‘negative’ and assigned an opioid-sparing
effect of zero. Due to variability in methodology and
reporting, within study comparisons of secondary
outcomes in treatment (NSAID or paracetamol) vs
placebo groups are reported as being increased,
decreased, or not different.
Results
Description and stratification of retrieved studies
The systematic literature search yielded 104 relevant
titles of which 31 met the inclusion criteria (Figure 1).
All included studies were placebo-controlled blinded tri-
als with quality scores of 3–5 on the Jadad scale (15).
Recruited children ranged in age from 1.5 months to
17 years old, and all received systemically administered
opioids for perioperative analgesia. Several studies
included multiple active treatment arms, but only those
allowing comparison of opioid consumption in an active
and placebo group were included. In total, 988 children
were allocated to placebo control arms, and 1636 chil-
dren received study drugs (paracetamol and/or NSA-
IDs). Numbers within treatment groups ranged from 13
to 84 subjects. Based on design methodology, studies
were stratified according to the availability of opioid
(continuous titration vs intermittent bolus) and the
duration of study drug administration (either repeat
dose for  24 h, or single dose  6 h) into four groups
(Group A–D; Figure 1).
In 10 of 31 studies, intravenous opioid was contin-
uously available for titration (Group A and B;
Table 1). Morphine (17–24) or fentanyl (25,26) was
administered via nurse-controlled (NCA; n = 2) or
patient-controlled (PCA; n = 8) bolus administration.
Records retrieved and screened 
(n = 104)
Studies included in qualitative 
synthesis (n = 31)
Records excluded, with reasons
n = 34; not NSAID or paracetamol
n = 14; not RCT design
n = 11; control/placebo group
n = 9; no opioid dose evaluation 
n = 2; non-opioid rescue
n = 2; adult studies
n = 1; variable regional anesthesia
Design: intermittent bolus opioid
(n = 21)
10 Fentanyl
4 Morphine
4 Pethidine
1 Oxycodone (iv or im)
1 Oxycodone or morphine
1 Piritamide
GROUP A
repeat dose study 
drug  24 h
(n = 7)*
3 Paracetamol
2 Ketorolac
1 Diclofenac
1 Indomethacin
1 Ketoprofen
1 Paracetamol + 
diclofenac
Design: continuous IV opioid 
titrated against response (n = 10)
PCA (n = 8)
o 7 Morphine
o 1 Fentanyl
NCA (n = 2)
o 1 Morphine
o 1 Fentanyl
GROUP C
repeat dose study 
drug  24 h
(n = 4)*
1 Ibuprofen
1 Indomethacin
1 Ketoprofen
1 Paracetamol
1 Diclofenac
1 Paracetamol + 
diclofenac
GROUP B
single dose study 
drug or  6 h
(n = 3)
1 Diclofenac
1 Ketoprofen
1 Ketorolac
GROUP D
single dose study 
drug or  6 h
(n = 17)*
5 Paracetamol
4 Ketorolac
6 Ketoprofen
1 Ibuprofen
1 Naproxen
1 Rofecoxib
1 Paracetamol + 
ibuprofen 
1 Paracetamol + 
ketorolac* Some studies included more than one active treatment arm
Figure 1 Flow chart of literature search with summary of excluded and included studies and grouping according to study design.
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Lockout periods ranged from 10 to 30 min for NCA
and 3 to 10 min for PCA, and a background infusion
was included in six studies (four PCA and both NCA
studies). In the 21 studies in Group C (27–30) and
Group D (31–46) (Table 2), opioid was available on
an ‘as needed’ or ‘PRN’ basis, with nurse administra-
tion triggered by a predetermined pain score using
either a formal assessment tool (16 studies) or global
nursing assessment and patient request (five studies)
(Table 3).
Across the 31 studies, thirty-eight different drug
groups were compared with placebo (Figure 1). Paracet-
amol and an NSAID were directly compared within four
studies, with three also evaluating the combination of
paracetamol and NSAID. Additional within study com-
parisons included dose-dependent effects of paracetamol
(37,39) or ketoprofen (41); different routes of adminis-
tration of ketoprofen (36,38,47); or administration of
ketorolac at the beginning or end of surgery (42). This
increased the number of groups in which opioid con-
sumption was measured to 48 treatment arms and 31
placebo controls (one per study) (Table 4).
Opioid consumption
Significant decreases in opioid consumption by NSAID
and/or paracetamol were reported in 21 of the 31 stud-
ies, four did not demonstrate any dose-sparing effects,
and in six studies, both positive and negative results
were reported for different treatment arms (Table 1 and
2). Overall, positive effects were reported in 38 of 48
treatment arms (Figure 2).
In Group A studies (seven studies with nine treat-
ment arms), surgery was of moderate to major sever-
ity, and systemic opioid was available for immediate
titration by the patient (PCA) or by nursing staff
(NCA bolus plus background). In addition, study
drug administration and evaluation continued for at
least 24 h following surgery. Seven of nine treatment
arms were positive. Two studies reported no signifi-
cant benefit with addition of rectal paracetamol
(17,20). Overall, opioid dose requirements were
reduced by 31.6% (95% CI: 16.5–46.6) (Table 4).
Opioid sparing was reported in all Group B studies,
with a mean reduction of 24.3%, but with wide vari-
ability, as only three studies were available.
Significant reduction in opioid dose was reported in
five of six treatment arms in Group C (mean 24.5%
95% CI 6.3–42.6) and in 23 of the 30 active treatment
arms in Group D (mean 24%; 95% CI: 16.4–31.5)
(Table 4). Overall, the majority of Group C/D studies
demonstrated significant opioid sparing, but with much
greater variability in reported results.
Paracetamol vs NSAID vs combination
A higher proportion of positive studies were reported in
NSAID (27 of 31; 87%) than in paracetamol (7 of 13;
54%) treatment arms. Four studies included direct com-
parison of an NSAID and paracetamol. Rectal diclofe-
nac (1 mgkg1 intraoperative and 8 hrly for 24 h)
produced opioid sparing, but by comparison, rectal par-
acetamol was less effective (40 mgkg1 intraoperative
and 30 mgkg1 8 hrly) (27) or showed no benefit
(20 mgkg1 loading and 15 mgkg1 6 hrly) (20). Ibu-
profen 15 mgkg1 PR was more effective than paracet-
amol 40 mgkg1 PR (27 vs 19% reduction) (35), and
preoperative oral administration of naproxen
10 mgkg1 was more effective than paracetamol
20 mgkg1 (19% vs nonsignificant difference) (33).
Positive opioid sparing by diclofenac (1 mgkg1 8 hrly
PR) was further enhanced by addition of paracetamol
30 mgkg1 8 hrly PR (27), but not by paracetamol
20 mgkg1 PR loading and 15 mgkg1 6 hrly (20).
While both paracetamol 40 mgkg1 PR and ibuprofen
15 mgkg1 PR reduced opioid requirements following
adenoidectomy, combining the two drugs provided no
additional benefit (35). A single combined dose of
ketorolac and paracetamol markedly reduced postanes-
thesia care unit (PACU) opioid requirements, but effects
of the individual drugs were not assessed (31).
Within study comparisons: dose response and route of
administration
Three studies included dose-response comparisons.
Dose-dependent increases in opioid sparing in PACU
were reported following 20, 40, and 60 mgkg1 rectal
paracetamol (27 vs 54 vs 73%, respectively) (39). Con-
versely, rectal paracetamol doses of 10, 20, or
40 mgkg1 had no significant effect in PACU following
cleft palate repair (37). Intravenous ketoprofen 0.3, 1,
and 3 mgkg1 reduced the proportion of children
requiring fentanyl for 2 h following adenoidectomy,
with minimal dose-related differences (21, 24, and 35%
reduction, respectively) (41).
Administration of the same dose of ketoprofen by dif-
ferent routes demonstrated benefit with intravenous but
not oral administration (47), and similar degrees of
opioid sparing following intravenous vs rectal (38) or
intramuscular administration (36). There have been no
direct comparisons of paracetamol by different routes.
Intravenous (26) but not rectal (17,20) paracetamol
reduced 24-h opioid requirements. Wide variability in
individual plasma paracetamol concentrations was
noted following rectal administration (0.8–59.9 mgl1)
(17).
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Pain assessment and pain scores
All studies incorporated pain assessment, but by a range
of different tools. Self-report included numerical rating
(0–3 or 0–10), visual analog scales (0–10 or 0–100) or
faces scales. Observer tools ranged from an overall
numerical rating to composite measures of specific
behavioral and physiological responses (e.g., Children’s
Hospital of Eastern Ontario Pain Scale (CHEOPS) and
COMFORT scales) (Table 3).
In Group A and B studies, intravenous bolus opioid
was triggered by the patient (PCA), who titrated them-
selves to similar pain scores in two of eight studies
(20,21). Six studies reported improved pain scores with
addition of NSAID/paracetamol. Outcomes included
different composite measures of pain (i.e., area under the
pain intensity–time graph for the first 24 h (18), a main
effect of treatment with repeated measures ANOVA to 36 h
(22), overall pain score for first 12 h (23)). Others
reported significant reductions in pain score only at some
time points (i.e., the first 48 h (19), the initial six postop-
erative hours (25) or the first hour in PACU (24)).
In NCA studies, a background infusion plus opioid
bolus administration by a nurse or trained parent
following urologic surgery (26), or by a nurse or investi-
gator in intensive care after major abdominal or thoracic
surgery (17), resulted in effective titration to similar pain
scores. In the latter study, a high proportion of patients
were mechanically ventilated, and both Observer VAS
and COMFORT scores were low in paracetamol and
placebo groups (17).
In Group C and D studies, opioid was available on an
‘as needed’ or ‘PRN’ basis. Nurse administration was
triggered by a predetermined pain score using a formal
assessment tool (16 studies) or global nursing assessment
and patient request (five studies). Pain scores in treat-
ment groups were reported to be significantly lower in
the active treatment arm in 10 studies; reduced in some
subgroups or on some subscales in 3; equivalent in 6;
and were not reported in two studies (Table 3).
Opioid-related adverse effects
Postoperative nausea and vomiting (PONV) was com-
pared in 27 of 31 studies, with six study arms in five
studies reporting a significant reduction in the paraceta-
mol and/or NSAID group (Table 3). The degree of
Figure 2 Percentage reduction in opioid requirements in pair-wise
comparisons of mean opioid dose requirements in active treatment
arms (paracetamol; NSAID; combination = NSAID + paracetamol) vs
control/placebo. Studies reporting no statistically significant differ-
ence from control are designated as 0% reduction. Solid line = mean
of NSAID arms; dotted line = mean of paracetamol arms. Treatment
groups comprise Group A = PCA/NCA + study drug 24 h; Group
B = PCA/NCA + study drug 6 h; Group C: intermittent opi-
oid + study drug  24 h; Group D = intermittent opioid + study drug
 6 h.
Table 4 Summary of study groups and degree of opioid sparing
Study design Group A Group B Group C Group D
No. of studies 7 3 4 17
No. of active treatment arms 9 3 6 30
Negative arms paracetamol (92) ketoprofen paracetamol (94)
ketoprofen
ketorolac
rofecoxib
Positive arms paracetamol
paracetamol + diclofenac
diclofenac
indomethacin
ketoprofen
ketorolac (92)
diclofenac
ketoprofen
ketorolac
paracetamol
paracetamol + diclofenac
diclofenac
ibuprofen
indomethacin
paracetamol (95)
paracetamol + ibuprofen
paracetamol + ketorolac
ibuprofen
ketoprofen (910)
ketorolac (94)
naproxen
% opioid reduction (mean) [95% CI] 31.6
[16.5–46.6]
24.3
[1.7–50.4]
24.5
[6.3–42.6]
24.0
[16.4–31.5]
Bold values indicates mean % change in opioid consumption.
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opioid sparing tended to be greater (47%, 95% CI 22–
72) in treatment groups with less PONV when compared
to studies with equivalent PONV (26%, 95% CI 20–31).
Within study comparisons found a significant reduction
in the incidence of PONV with 40 and 60 mgkg1 PR,
but not 20 mgkg1 which also had less effect on opioid
requirement (39). Preoperative, but not postoperative,
ketorolac reduced both opioid requirement and the
number of children vomiting following tonsillectomy
(42).
Ten studies noted no difference in significant adverse
respiratory effects, reported as either a lack of respira-
tory depression or no difference in respiratory rate or
episodes of desaturation. Sedation was assessed in 17 of
31 studies: 14 reported no difference, and three studies
with positive opioid sparing also reported less sedation
in the active treatment group. The incidence of overse-
dation (defined as Ramsay sedation score >4 on 8-point
scale) was reduced when paracetamol (26) or ketorolac
plus paracetamol (31) was used with fentanyl NCA; and
‘somnolence’ and IV fentanyl bolus use in PACU was
less frequent with addition of ketoprofen (43).
No difference in adverse urinary effects (i.e., need for
catheterization or difficulty voiding) was noted in nine
studies, but fewer children required a urinary catheter
following orthopedic surgery if they received IV ketoro-
lac (1 of 25 vs 7 of 25 in the control group) (23). Six
studies recorded pruritus, but there were no differences
between treatment and control groups.
NSAID/paracetamol adverse effects
No cases of accidental overdose or toxicity related to
paracetamol were reported.
Alteration in bleeding was the main potential NSAID
adverse effect evaluated, particularly as many studies
were conducted in children undergoing tonsillectomy.
The incidence or degree of perioperative bleeding was
reported in 21 NSAID studies: seven each of ketoprofen
or ketorolac, two of diclofenac or ibuprofen, and single
studies of naproxen or rofecoxib. Bleeding following
paracetamol was assessed in three studies, of which two
included an NSAID treatment arm. Methods for report-
ing this outcome varied and included the following:
direct measurements of intraoperative blood loss or
postoperative blood loss in drains; graded but subjective
assessments of intraoperative blood loss by the surgeon;
rate of re-operation/interventions to control increased
bleeding; or statements that no patients had significant
bleeding. Following tonsillectomy and/or adenoidec-
tomy, measured perioperative blood loss was not
increased following ketorolac 1 mgkg1 (42) or keto-
profen (25,28). Graded assessment of blood loss by the
surgeon found no increase in intraoperative bleeding
with ketorolac (45), ibuprofen (35), or ketoprofen
(25,36,38,41). Although not quantified, no cases of
increased bleeding were reported following rofecoxib
(34), naproxen (33), or paracetamol (32,33). In one
study, the rate of ‘more than normal’ bleeding was
greater following ketoprofen (12 of 80 vs 3 of 84;
P = 0.037), but no patients required re-operation (43).
Cases of bleeding requiring reoperation were reported in
both placebo and/or NSAID groups. Two patients were
excluded from analysis following ketorolac as they
required an immediate return to the operating theater to
control surgical bleeding (42); one patient was with-
drawn due to bleeding at 5 h following ketoprofen (18);
two patients required diathermy under local anesthesia
at 4 or 26 h following ketoprofen (28); and one patient
required nasopharyngeal packing overnight following
diclofenac (24). Bleeding requiring surgical intervention
was also reported in three patients given placebo
(24,25,46).
Measured blood loss did not differ from control
groups during spinal fusion with ketorolac (19) or oph-
thalmic, general or orthopedic surgery with ibuprofen
(29). No significant episodes of bleeding were reported
with diclofenac for cleft palate repair (27), or with ket-
orolac for orthopedic (23) or day case general surgery
(44), despite a greater increase in measured bleeding
time (53.4  74.8 s) in the latter study.
Patient/parent satisfaction
Relatively few studies evaluated overall satisfaction with
treatment, and none included patient satisfaction as an
outcome. Higher levels of parental satisfaction in the
active treatment arm either during the in-hospital stay
(26,31) or during both the time in hospital and following
discharge (34) were reported. No comparison was made
with patient satisfaction, but these studies enrolled
infants (26,31) or young children (>3 years; mean
7 years) (34).
Discussion
Recommendations to use multimodal analgesic therapy
for perioperative pain management in children (3,7) are
supported by this qualitative systematic review. Across
31 studies, 38 of 48 active treatment arms reported a sta-
tistically significant reduction in opioid requirements
with co-administration of NSAID and/or paracetamol
in pair-wise comparisons with a placebo group. How-
ever, potential publication bias against negative studies
cannot be excluded. Evidence for a clinical advantage in
terms of improved pain scores or a reduction in adverse
© 2013 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd
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effects was less robust. However, variability in study
design, method of opioid delivery, duration of study
drug administration, and reported outcome measures
had an impact on the likelihood and degree of positive
findings.
Opioid dose requirements
Opioid-sparing effects with perioperative NSAIDs and
paracetamol have been well documented in meta-analy-
ses of adult studies (10,11,48), using a standardized mea-
sure of opioid dose (24 h total PCA morphine
consumption) (10)[additional details in (8)]. In the cur-
rent pediatric series, all studies that evaluated cumula-
tive PCA morphine dose (mcgkg1day1 in children
aged at least 5 years) reported significant reductions in
opioid requirements in the first 24 h by regular doses of
NSAID (18–22,25)) and in the early postoperative per-
iod by a single dose of diclofenac (24) or ketorolac (23).
These studies were also included in a meta-analysis of 28
pediatric studies, which calculated the standardized
mean difference in opioid requirements for individual
trials, and reported significant opioid sparing in PACU
and during the first 24 h by NSAID (13). We have also
evaluated studies of perioperative paracetamol and
found more variable results: rectal paracetamol did not
reduce PCA (20) or NCA (17) opioid requirements, but
IV paracetamol reduced NCA opioid requirements in
children aged 6–24 months (26).
Variable methodology in pediatric analgesic studies
influences the sensitivity for detecting differences and
the ability to combine data across studies (14,49). Mich-
elet and colleagues (13) also noted significant heteroge-
neity, but benefit with NSAID was maintained in
subgroup analyses of the effects of surgery (adenotonsil-
lectomy vs orthopedic or general surgery) and timing of
administration (intra- vs postoperative NSAID) (13). In
the current studies, the degree of opioid sparing tended
to be higher and more consistent when opioid was read-
ily available for titration (i.e., PCA or NCA) and
repeated doses of study drug were given (i.e., Group A
design). Studies with opioid available on an intermittent
‘PRN’ basis and evaluating the effect of a single dose of
NSAID/paracetamol (i.e., Group D design) also
reported significant opioid sparing, but there was much
greater variability in the degree of difference and in the
outcome being evaluated. Many were conducted follow-
ing surgery with relatively low analgesic requirements,
and group data such as the proportion of patients
requiring opioid in PACU, rather than individual dose
requirements, were the primary outcomes. Some statisti-
cally significant differences may have limited clinical
significance (e.g., mean differences of less than one dose
per patient). In addition, the duration of follow-up was
often limited to time in the PACU or the first 1–2 post-
operative hours, with only one study reporting a reduc-
tion in analgesic requirements following discharge (39).
Reduction in PACU opioid requirements with NSAID
has also been confirmed by meta-analysis (13) and while
reducing early postoperative pain is clearly important,
the greater clinical challenge may be to determine
whether this translates into reduced analgesic require-
ments or improved analgesia following discharge.
Recent studies confirm that many children experience
significant levels of pain at home (50,51), and provision
of adequate analgesia following discharge remains an
unmet need.
Analgesic efficacy
Recruiting children across wide age ranges necessitates
use of different measurement tools, and standardized
use of validated measures has been advocated (52) to
improve comparison across studies. The observer and
self-report pain assessment tools used in the reviewed
studies have variable numbers of choices and different
linear/ratio characteristics, making it difficult to com-
pare absolute changes in pain ‘score’ or intensity or to
evaluate an overall change over time. Pain intensity is
often not evaluated in adult analyses as it is assumed
that patients will titrate themselves to similar levels of
analgesia (10,11); but one analysis found pain intensity
was reduced at 24 h by multidose NSAID, but not sin-
gle-dose NSAID or paracetamol (48). In the pediatric
meta-analysis, addition of NSAIDs to opioids reduced
pain intensity in the PACU but not the first 24 h (13). In
6 of the 8 PCA studies reviewed here, pain scores were
lower in the active treatment arms, despite these older
children being able to ‘self-titrate’ their analgesia. It is
possible children may tolerate higher levels of pain to
avoid opioid-related PONV, as has been suggested in
adult studies (12). Intermittent opioid administration by
a nurse can have less flexible dosing schedules, addi-
tional time constraints, and is reliant on the frequency
and sensitivity of pain assessment. Nine of 12 Group D
studies reported lower pain scores, suggesting that inter-
mittent dosing in the early postoperative period was less
effective for titrating analgesia in the placebo groups.
Analgesic trials in children can pose ethical chal-
lenges, particularly in the use of placebo control groups
(53). Using a rescue-analgesic design with analgesic
sparing as a surrogate efficacy endpoint incorporates the
scientific and regulatory advantages of placebo-
controlled trials, while ensuring children have analgesia
available for immediate titration (53). All studies
included in this analysis had opioid available for
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titration postoperatively, either by PCA/NCA or by
intermittent bolus. In the majority of studies, both
NSAID/paracetamol and placebo treatment arms also
received standardized intraoperative opioid and/or local
anesthetic infiltration. In some early Group C/D studies,
intraoperative analgesia was limited to nitrous oxide
alone (29,30,39,44–46). Opioid was available for titra-
tion in PACU, and all studies reported significantly
higher analgesic requirements in the placebo group
(29,30,39,44–46). Differences in intraoperative analgesia
may also contribute to a cross-study variability in opioid
sparing, particularly when assessment is limited to the
first few postoperative hours.
Opioid-related adverse effects
Although statistically significant reductions in opioid
requirements demonstrate analgesic benefit, clinical ben-
efit is enhanced if there is also a reduction in opioid-
related adverse effects. Individual studies are rarely
powered for these secondary outcomes and definitions
or thresholds for reporting adverse effects vary across
studies. Postoperative vomiting is an important cause of
morbidity, a leading concern for parents and patients,
and may require readmission (54,55). In the first 24 post-
operative hours, NSAIDs had a similar impact on
PONV in meta-analyses of adult (odds ratio 0.7, 95%
CI 0.53–0.88) (10) and pediatric (odds ratio 0.75, 95%
CI 0.57–0.99) (13) studies. In addition to patient (i.e.,
age, gender) and anesthetic factors, the type of surgery
can have a significant effect. Many pediatric studies
have been conducted following tonsillectomy, which has
a high rate of PONV, and NSAIDs had a greater impact
in this subgroup (13). There have been insufficient stud-
ies to specifically evaluate PONV in other high-risk sur-
gical groups, such as strabismus, although beneficial
effects of NSAID on both opioid sparing and vomiting
have been reported (40). Although some studies evalu-
ated the number of episodes of vomiting in individual
children (28,40), the majority of studies reported the
incidence of vomiting within treatment arms, and it was
not possible to differentiate effects on the frequency or
severity of vomiting. Other opioid-related adverse
effects, such as urinary retention and pruritus are less
common, are less likely to be reported in individual
studies, and no significant differences were reported in a
meta-analysis (13).
Respiratory depression is the most feared adverse
effect of opioids, with an incidence in large pediatric
audits (>10 000 patients) of 0.13% with opioid via
continuous infusion, PCA, or NCA (1) and 0.4% with
opioid NCA in a younger population (2). Clinical trials
are not powered to evaluate this rare outcome and
often exclude patients shown to be at highest risk (i.e.,
neonates, particularly those born preterm, and patients
with comorbid conditions such as cardiorespiratory dis-
ease and neurodevelopmental impairment) (1,2).
Increased sedation, which can be a more reliable indica-
tor of impending respiratory depression, was noted in
some placebo groups, but was not sufficient to be associ-
ated with respiratory depression or oxygen desaturation.
(26,31,43).
Type of surgery
Studies included here and in previous analyses of periop-
erative opioid dose requirements in children (7,13)
include patients undergoing a range of different surger-
ies, with variable perioperative analgesic requirements.
When opioid requirements were relatively high and
administration via NCA or PCA was required, results
were less variable and the ability to detect significant
differences with co-administration of NSAIDs was
enhanced. NSAIDs may have specific efficacy against
bone pain, and one within study comparison showed
benefit with ibuprofen following orthopedic but not gen-
eral surgery (29). Tonsillectomy not only has an impact
on potential opioid-related adverse effects such as
PONV, but analgesic benefits must also be weighed
against the potential for NSAID-induced bleeding.
Cases of post-tonsillectomy bleeding were noted in both
NSAID and placebo groups but the number requiring
intervention was small. Meta-analyses of pediatric stud-
ies have concluded that the risk of bleeding requiring
reoperation is not increased by diclofenac for acute pain
(56) or NSAIDs following tonsillectomy (57).
Comparison of study drugs
There is currently insufficient data to determine the
relative efficacy of paracetamol or different NSAIDs,
and the dose equivalence of different preparations at
different ages is not well-established. Overall, the pro-
portion of positive studies was lower with paraceta-
mol, and adult analyses also suggest a greater degree
of opioid sparing with NSAIDs vs paracetamol (10).
However, pediatric studies may also be confounded by
inadequate paracetamol dosing and variability in
absorption, particularly when given by the rectal route
(17). Within study comparisons found dose-dependent
increases in opioid sparing with higher rectal paraceta-
mol dose (37,39). The time to peak plasma concentra-
tion varies with the rectal preparation, but can exceed
2 h (58,59). In addition, the equilibration half-life (teq)
for the analgesic effect compartment is over 50 min,
which further delays time to maximum analgesia (60).
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As a result, an adequate effect site concentration may
not be achieved following administration of single
doses for relatively brief surgical procedures with eval-
uation in PACU; a design commonly utilized in the
studies classified here as Group D, which show wide
variability in reported opioid sparing and the greatest
number of negative paracetamol studies. Intravenous
paracetamol was beneficial in 2 included studies
(26,31) and has recently been reported to reduce opi-
oid requirements in neonates and infants following
major surgery (61). Recent pharmacokinetic analyses
provide further data regarding appropriate dose sched-
ules for intravenous paracetamol (62,63).
Combining an NSAID and paracetamol produced
variable benefit in individual studies. Using time-effect
profiles at different doses, a recent simulation with par-
acetamol and ibuprofen suggests analgesic benefit with
this combination is more likely to be seen with modest
doses of drug and at time points beyond PACU (i.e.,
>2 h) (64). High doses of NSAID approach a maximum
or ceiling effect, and little additional benefit may be
gained by adding paracetamol (64). Additive analgesia
with paracetamol and NSAID has been demonstrated
in adults with acute pain (9,16,65), and although
co-administration did not significantly alter opioid
requirements, meta-analysis of pediatric studies reported
a further reduction in pain intensity during the first 24 h
when regular paracetamol was added to NSAID (13).
Limitations and future directions
The current systematic review is limited to a qualita-
tive analysis; however, findings are consistent with a
recent meta-analysis which evaluated the impact of
NSAID on postoperative opioid requirements in chil-
dren (13). This meta-analysis provides more detailed
quantification of the degree (i.e., standardized mean
difference) in opioid requirement, and by combining
data for secondary outcomes, such as PONV, can bet-
ter evaluate effects for which individual studies are
inadequately powered. However, significant heteroge-
neity is often seen in pediatric analgesic studies, with
variability in design, study population, and outcome
measures. Qualitative reviews can provide further
information about which clinical populations are most
likely to benefit from the intervention and highlight
areas requiring further research. There is an ongoing
need for more uniform use of validated pain scores
and outcome measures (52) to facilitate comparison
and combination of data from different trials. Stan-
dardized definitions and reporting of adverse effects or
clinical endpoints such as PONV, pruritus, and seda-
tion would also enhance evaluation of relative risks
and benefits. Further quantification of clinically signifi-
cant benefits is likely to require much larger or multi-
center studies that are sufficiently powered to detect
differences in adverse effects rather than just differ-
ences in opioid consumption (10) and/or that have
more prolonged follow-up that includes evaluation of
pain and function following discharge after short-stay
or day case surgery.
Conclusion
NSAIDs and/or paracetamol reduce perioperative
opioid requirements in children, and positive effects are
most consistently seen when opioid requirements are rel-
atively high and titrated by NCA or PCA. The degree of
clinically significant benefit in terms of improved analge-
sic benefit or reduction in opioid-related adverse effects
varies across studies, and there is currently insufficient
data to compare the relative efficacy of different drugs.
The doses of NSAIDs and/or paracetamol utilized in
these trials were not associated with any additional
adverse effects. These data provide further support for
use of multimodal analgesia for perioperative pain in
children.
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